^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | MYX2449 (HER2-targeted antibody-drug conjugate, NMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
N-Myristolytransferase (NMT) inhibitors as novel potent payloads for antibody drug conjugates
Published date:
04/04/2023
Excerpt:
These ADCs were tested in vitro in cell killing studies using Her2+ and Her2- cell lines and subsequently tested in vivo in breast cancer and gastric cancer xenografts….Our first Trastuzumab-NMT inhibitor ADC (MYX2449) caused cell death in Her2+ BT474 cells with an EC50 of 0.2nM and peaking after 8 days of incubation, but was inactive against Her2- cells MCF7 at concentrations up to 100nM.
DOI:
https://doi.org/10.1158/1538-7445.AM2023-2635
